India Drug Firms Look Abroad For Trials, Government Tries To Trim Delays
This article was originally published in PharmAsia News
India's Serum Institute faced more than a year's delay getting approval for a Phase III trial for a rotavirus vaccine, leading it to look elsewhere for clinical trials of other vaccines, its executive director said.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.